Gemcitabine and paclitaxel are among the most active new agents in non-small cell lung
cancer (NSCLC) and are worth considering for second-line chemotherapy. In this phase I–II …

… 1.79, p < 0.01) among lung cancer patients. Furthermore, in the subgroup analyses …
pretreatment LMR seemed to be unrelated to the poorer OS of small cell lung cancer (SCLC) patients …

… /ex‐smokers and patients with a PS score of 2. It is reasonable to refer pretreated patients with
a … Waterfall plot of patients with non‐small cell lung cancer treated in phase I clinical trials. …

… In our study, we found that 58 patients (23%) had pretreatment TLC less than the lower limit
of normal (1.0 × 10 3 /µL), and we found that pretreatment TLC less than the median of 1.5 × …

… that elevated pretreatment NLR was associated with poor prognosis for small cell lung
cancer (SCLC). In the present study, we first explored the prognostic value of pretreatment NLR …

… non-small-cell lung cancer (NSCLC) with a risk of myelotoxicity. This study evaluated the
efficacy and toxicity profile of two docetaxel regimens in NSCLC patients who had failed first-…

… The present study was undertaken to gain insight into pretreatment patient characteristics
that could influence survival in patients with Stage III NSCLC treated with hyperfractionated …

… between pretreatment serum LDH and survival in SCLC patients. … that pretreatment serum
LDH ≥215.70 U/L is significantly correlated to prognosis. Hence, the correlation of pre-treated …

BACKGROUND: Neuron-specific enolase (NSE) is the most sensitive tumour marker for
small-cell lung carcinoma (SCLC) at the time of diagnosis. The main purpose of this study was to …

… Lung cancer is one of the leading causes of cancer death worldwide 1 . Non-small cell lung
cancer (NSCLC) comprises 85% of all lung cancers 2 . Despite recent advances in treatment …